Multiple myeloma - historical
Carboplatin & Paclitaxel (CP)
CP: Carboplatin & Paclitaxel
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Forde et al. 2022 (CheckMate 816) | 2017-2019 | Phase 3 (C) | 1a. CP & Nivolumab 1b. CVb & Nivolumab 1c. DC & Nivolumab |
Inferior EFS |
Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details. This study was conducted in the United States. The reason for the study was that an unanswered question at the time was whether adding an immune checkpoint inhibitor would improve outcomes.
Biomarker eligibility criteria
- CheckMate 816: No sensitizing EGFR or ALK mutations
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 or 6 IV once on day 1
- Paclitaxel (Taxol) 175 or 200 mg/m2 IV once on day 1
21-day cycle for 3 cycles
Subsequent treatment
References
- CheckMate 816: Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. Epub 2022 Apr 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02998528
Start of hidden/commented information for virtual editor End of hidden/commented information for virtual editor
Start of comment inserted by visual editor(edited again by visual editor)
(edited again by visual editor end)End of comment inserted by visual editor
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main multiple myeloma regimen page to find other regimens.
49 regimens on this page
88 variants on this page
|
First-line therapy
C-VAMP
back to top |
C-VAMP: Cyclophosphamide, Vincristine, Adriamycin (Doxorubicin), MethylPrednisolone
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Raje et al. 1997 | Phase III | VAMP | |
Child et al. 2003 (MRC Myeloma VII) | Phase III | ABCM | Seems to have superior OS |
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg IV once per day on days 1, 8, 15
- Cyclophosphamide was omitted in patients with a serum creatinine greater than 3.4 mg/dL
- Vincristine (Oncovin) 0.4 mg IV once per day on days 1 to 4 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 4 days (total dose per cycle: 36 mg/m2) on days 1 to 4
- Methylprednisolone (Solumedrol) 1000 mg/m2 (maximum dose per cycle of 1500 mg) PO/IV once per day on days 1 to 5
21-day cycles, given until maximal response was achieved
A minimum of 3 cycles given before stem cell harvest. Patients in MRC Myeloma VII proceeded to cyclophosphamide & G-CSF stem cell mobilization and high-dose melphalan & methylprednisolone with auto HSCT.
References
- Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997 Apr;97(1):153-60. link to original article PubMed
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. link to original article contains verified protocol PubMed
EDAP
back to top |
EDAP: Etoposide, Dexamethasone, Ara-C (Cytarabine), Platinol (Cisplatin)
Regimen
Study | Evidence |
---|---|
Barlogie et al. 1999 (Total Therapy) | Non-randomized |
Given as a component of Total Therapy.
Chemotherapy
References
- Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999 Jan 1;93(1):55-65. link to original article PubMed
RD
back to top |
RD: Revlimid (Lenalidomide) & high-dose Dexamethasone
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Rajkumar et al. 2009 (ECOG E4A03) | Phase III | Rd | Inferior OS |
This is the high-dose dexamethasone arm, and was intended for patients with previously untreated symptomatic multiple myeloma, bone marrow plasmacytosis (greater than or equal to 10% plasma cells or sheets of plasma cells) or a biopsy-proven plasmacytoma, and measurable disease defined as serum monoclonal protein more than 1 g/dL and/or urine monoclonal protein greater than or equal to 200 mg/24 h.
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
Supportive medications
- One of the following bisphosphonates:
- Pamidronate (Aredia) 90 mg IV over 2 to 4 hours once every 28 days
- Zoledronic acid (Zometa) 4 mg IV over 15 minutes once every 28 days
- Thromboprophylaxis mandatory (added mid-protocol after excess rates of DVT)
28-day cycle for 4 cycles (see below)
Responding patients could choose after 4 cycles to proceed to high-dose melphalan with autologous hematopoietic stem cell transplant or to continue RD until progression of disease or intolerable toxicity; nonresponders were transitioned to Thal-Dex (details not described).
References
- Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11(1):29-37. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11(1):14. link to original article contains verified protocol link to PMC article PubMed
VAD
back to top |
VAD: Vincristine, Adriamycin (Doxorubicin), Dexamethasone
VAd: Vincristine, Adriamycin (Doxorubicin), low-dose dexamethasone
Note: VAD is given as a bolus or a continuous infusion regimen; see variants for details.
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Sonneveld et al. 2012 (HOVON-65/GMMG-HD4) | Phase III | PAD | Seems to have inferior OS |
This regimen was intended for patients 18 to 65 years of age with newly diagnosed MM, Durie-Salmon stage II to III, WHO performance status 0 to 2, or WHO 3 when caused by MM. Observed efficacy is for induction PAD, then transplant, then maintenance bortezomib compared with induction VAD, then transplant, then maintenance thalidomide.
Chemotherapy
- Vincristine (Oncovin) 0.4 mg IV once per day on days 1 to 4
- Doxorubicin (Adriamycin) 9 mg/m2 IV once per day on days 1 to 4
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
Supportive medications
- One of the following bisphosphonates recommended:
- Pamidronate (Aredia) 90 mg IV once every 4 to 6 weeks x at least 2 years
- Zoledronic acid (Zometa) 4 mg IV once every 4 to 6 weeks x at least 2 years
- Ibandronate (Boniva) 6 mg IV once every 4 to 6 weeks x at least 2 years
- "Prophylactic antibiotics" (no further specifics) during induction therapy
- Erythropoietin and pain medications at physician discretion
- One of the following for Herpes zoster prophylaxis throughout bortezomib induction:
- Acyclovir (Zovirax) 800 mg PO per day (did not specify whether taken once per day or as a divided twice per day dose)
- Valacyclovir (Valtrex) 1000 mg PO per day (did not specify whether taken once per day or as a divided twice per day dose)
28-day cycle for 3 cycles
Stem cells collected 4 to 6 weeks after induction therapy; patients proceed to receive single autologous hematopoietic cell transplant (HOVON-65) or tandem autologous hematopoietic cell transplant (GMMG-HD4).
Regimen #2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Harousseau et al. 2010 (IFM 2005-01) | Phase III | VD | Might have inferior PFS |
This regimen was intended for patients age less than or equal to 65 years with untreated symptomatic MM with measurable paraprotein in serum (greater than 1.0 g/dL) or urine (greater than 0.2 g/24 h).
Chemotherapy
- Vincristine (Oncovin) 0.4 mg/day IV continuous infusion over 4 days on days 1 to 4 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 4 days on days 1 to 4 (total dose per cycle: 36 mg/m2)
- Dexamethasone (Decadron) as follows:
- Cycles 1 & 2: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
- Cycle 3 onwards: 40 mg PO once per day on days 1 to 4
Supportive medications
- Pamidronate (Aredia) 90 mg or Zoledronic acid (Zometa) 4 mg IV once every 28 days until first transplant
- "Antibiotics, antifungal agents, and antiviral prophylaxis in accordance with local practice."
28-day cycle for 4 cycles
Patients were then randomized to DCEP consolidation or went directly to autologous hematopoietic cell transplant.
Regimen #3, "VAd"
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Rifkin et al. 2006 | Phase III | DVd | Non-inferior ORR |
This regimen was intended for patients greater than or equal to 18 years and fulfilling a diagnosis of stage II or III MM according to the Durie and Salmon criteria.
Chemotherapy
- Vincristine (Oncovin) 0.4 mg/day IV continuous infusion over 96 hours on days 1 to 4 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 96 hours on days 1 to 4 (total dose per cycle: 36 mg/m2)
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
28-day cycles
Regimen #4, VAD bolus
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Dimopoulos et al. 2003 | Phase III | VAD doxil | Seems not superior |
This regimen was intended for all patients with previously untreated multiple myeloma who were considered candidates for systemic treatment.
Chemotherapy
- Vincristine (Oncovin) 0.4 mg IV over 30 minutes once per day on days 1 to 4
- Doxorubicin (Adriamycin) 9 mg/m2 IV over 30 minutes once per day on days 1 to 4
- Dexamethasone (Decadron) as follows:
- Cycles 1 & 3: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
- Cycles 2 & 4: 40 mg PO once per day on days 1 to 4
Supportive medications
- Fluconazole (Diflucan) 200 mg PO once per day
- Trimethoprim/Sulfamethoxazole 960 mg (paper did not specify which component was 960 mg) PO BID for "prophylaxis"
28-day cycle for 4 cycles
Regimen #5
Study | Evidence |
---|---|
Barlogie et al. 1984 | Phase II |
Barlogie et al. 2006 (SWOG S9321) | Non-randomized portion of RCT |
Chemotherapy
- Vincristine (Oncovin) 0.4 mg/day IV continuous infusion over 96 hours on days 1 to 4 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 96 hours on days 1 to 4 (total dose per cycle: 36 mg/m2)
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
Supportive medications
- Cimetidine (Tagamet) prophylaxis (dose not specified)
- Trimethoprim/Sulfamethoxazole prophylaxis (dose not specified)
35-day cycles
In Barlogie et al. 1984, treatment was given "until a maximum reduction in myeloma protein had occurred" and patients received four additional cycles of therapy beyond their best response. In SWOG S9321, patients with at least stable disease were randomized after 4 cycles to VBMCP versus melphalan & TBI, then auto HSCT.
Regimen #6
Study | Evidence |
---|---|
Segeren et al. 1999 | Phase II |
Chemotherapy
- Vincristine (Oncovin) 0.4 mg IV over 30 minutes once per day on days 1 to 4
- Doxorubicin (Adriamycin) 9 mg/m2 IV over 30 minutes once per day on days 1 to 4
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 of odd-numbered cycles only
Supportive medications
- Fluconazole (Diflucan) 200 mg PO once per day
- Trimethoprim/Sulfamethoxazole 960 mg (paper did not specify which component was 960 mg) PO BID for "prophylaxis"
28-day cycles
Regimen #7
Study | Evidence |
---|---|
Cavo et al. 2007 (Bologna 96) | Non-randomized portion of RCT |
This regimen was intended for patients with a confirmed diagnosis of symptomatic or progressive MM, an upper age limit of 60 years, and previously untreated.
Chemotherapy
- Vincristine (Oncovin) 0.4 mg/day IV continuous infusion over 4 days on days 1 to 4 (total dose per cycle: 1.6 mg)
- Doxorubicin (Adriamycin) 9 mg/m2/day IV continuous infusion over 4 days on days 1 to 4 (total dose per cycle: 36 mg/m2)
- Dexamethasone (Decadron) as follows:
- Cycles 1 & 3: 40 mg PO once per day on days 1 to 4
- Cycles 2 & 4: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
28-day cycle for 4 cycles
Responders were randomized to single autologous hematopoietic cell transplant versus tandem autologous hematopoietic cell transplant.
References
- Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984 May 24;310(21):1353-6. link to original article contains verified protocol PubMed
- Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol. 1999 Apr;105(1):127-30. link to original article contains verified protocol PubMed
- Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003 Jul;14(7):1039-44. link to original article contains protocol PubMed
- Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5. link to original article PubMed
- Update: Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL; IFM Group. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008 Nov 1;112(9):3914-5. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006 Feb 15;106(4):848-58. link to original article contains verified protocol PubMed
- Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Yakoub Agha I, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet-Loiseau H, Moreau P, Facon T; Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006 Nov 15;108(10):3289-94. Epub 2006 Jul 27. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007 Jun 10;25(17):2434-41. Epub 2007 May 7. link to original article contains verified protocol PubMed
- Sub-group analysis: Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10. link to original article contains protocol PubMed
- Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added]. link to original article refers to protocol in Barlogie et al. 1984 PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article link to PMC article PubMed
- Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. link to original article contains verified protocol PubMed
- Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010 Oct 20;28(30):4621-9. Epub 2010 Sep 7. link to original article contains protocol PubMed
- Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012 Aug 20;30(24):2946-55. Epub 2012 Jul 16. link to original article contains verified protocol PubMed
VAMP
back to top |
VAMP: Vincristine, Adriamycin (Doxorubicin), MethylPrednisolone
Regimen
Study | Evidence | Comparator |
---|---|---|
Raje et al. 1997 | Phase III | C-VAMP |
Chemotherapy
References
- Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997 Apr;97(1):153-60. link to original article PubMed
- Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998 Nov 1;92(9):3131-6. link to original articlePubMed
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. link to original article PubMed
- Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005 Dec 20;23(36):9227-33. Epub 2005 Nov 7. link to original articlePubMed
VBMC
back to top |
VBMC: Vincristine, BiCNU (Carmustine), Melphalan, Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Child et al. 2003 (MRC Myeloma VII) | Phase III | Melphalan & Methylprednisolone, then auto HSCT | Seems to have inferior OS |
Chemotherapy
Followed by interferon alfa maintenance.
References
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. link to original article PubMed
VBMCP
back to top |
VBMCP: Vincristine, BiCNU (Carmustine), Melphalan, Cyclophosphamide, Prednisone
Regimen
Study | Evidence | Comparator |
---|---|---|
Barlogie et al. 2006 (SWOG S9321) | Phase III | Melphalan & TBI, then auto HSCT |
Chemotherapy
- Vincristine (Oncovin)
- Carmustine (BiCNU)
- Melphalan (Alkeran)
- Cyclophosphamide (Cytoxan)
- Prednisone (Sterapred)
References
- Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added]. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
VBMCP/VBAD
back to top |
VBMCP: Vincristine, BiCNU (Carmustine), Melphalan, Cyclophosphamide, Prednisone
VBAD: Vincristine, BiCNU (Carmustine), Adriamycin (Doxorubicin), Dexamethasone
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Bladé et al. 2005 (PETHEMA) | Phase III | VBMCP/VBAD, then MEL-200, then auto HSCT VBMCP/VBAD, then MEL-140 & TBI, then auto HSCT |
Seems not superior |
Note: it is not clear from the manuscript what the primary endpoint was. While this regimen had inferior CR, there was no difference in PFS or OS.
Chemotherapy, VBMCP portion
- Vincristine (Oncovin)
- Carmustine (BiCNU)
- Melphalan (Alkeran)
- Cyclophosphamide (Cytoxan)
- Prednisone (Sterapred)
Chemotherapy, VBAD portion
References
- Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005 Dec 1;106(12):3755-9. Epub 2005 Aug 16. link to original article PubMed
VMCP
back to top |
VMCP: Vincristine, Melphalan, Cyclophosphamide, Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Fermand et al. 2005 | Phase III | VAMP, then auto HSCT | Might have inferior EFS |
Chemotherapy
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
- Melphalan (Alkeran) 6 mg/m2 PO once per day on days 1 to 4
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Prednisone (Sterapred) 80 mg/m2 PO once per day on days 1 to 4
Monthly cycles
References
- Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005 Dec 20;23(36):9227-33. Epub 2005 Nov 7. link to original articlecontains verified protocol PubMed
VMCP/BVAP
back to top |
VMCP: Vincristine, Melphalan, Cyclophosphamide, Prednisone
BVAP: BiCNU (Carmustine), Vincristine, Adriamycin (Doxorubicin), Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Attal et al. 1996 | Phase III | VMCP/BVAP alone | Seems to have superior OS |
Chemotherapy, VMCP portion
- Vincristine (Oncovin) 1 mg IV once on day 1
- Melphalan (Alkeran) 5 mg/m2 PO once per day on days 1 to 4
- Cyclophosphamide (Cytoxan) 110 mg/m2 PO once per day on days 1 to 4
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 4
21-day cycle for 2 to 3 cycles, given in an alternating fashion with BVAP
Chemotherapy, BVAP portion
- Carmustine (BiCNU) 30 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1 mg IV once on day 1
- Doxorubicin (Adriamycin) 30 mg/m2 IV once on day 1
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 4
21-day cycle for 2 to 3 cycles, given in an alternating fashion with VMCP
VMCP and BVAP are given in an alternating fashion x a total of 4 to 6 cycles
Patients with a WHO performance status less than 3, creatinine less than 1.7 mg/dL (150 µmol/L), and bone marrow (collected after cycle 4) with greater than 200 million nucleated cells/kg would proceed to melphalan, total body irradiation (TBI), and autologous transplant.
References
- Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7. link to original article contains verified protocol PubMed
Consolidation after first-line therapy
Melphalan monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
McElwain, Powles 1983 | Pilot Study |
Note that this is highly obsolete but included for historical interest. Stem cell rescue was NOT used.
Chemotherapy
- Melphalan (Alkeran) 100 to 140 mg/m2 IV once
References
- McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983 Oct 8;2(8354):822-4. link to original article PubMed
- Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007 Jul;92(7):928-35. link to original article PubMed
Melphalan, then auto HSCT, then Melphalan & Busulfan, then auto HSCT
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Cavo et al. 2007 (Bologna 96) | Phase III | Melphalan, then auto HSCT | Superior EFS |
Chemotherapy, first transplant
- Melphalan (Alkeran) 200 mg/m2 IV once on day -2
Stem cells re-infused on day 0
Chemotherapy, second transplant
- Melphalan (Alkeran) 120 mg/m2 IV once on day -4
- Busulfan (Myleran) 4 mg/kg PO from day -5 to -3
Stem cells re-infused on day 0
References
- Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007 Jun 10;25(17):2434-41. Epub 2007 May 7. link to original article contains verified protocol PubMed
MEL200, then auto HSCT, then MEL220 & Dexamethasone, then auto HSCT
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Moreau et al. 2005 (IFM 99-04) | Phase III | MEL200, then MEL220 + Dex + B-E8 | Seems not superior |
This regimen was meant for patients who did not have an HLA-identical sibling donor.
Preceding treatment
- VAD induction x 4
Chemotherapy, first transplant
- Melphalan (Alkeran) 200 mg/m2 IV once on day -2
Stem cells re-infused on day 0
Chemotherapy, second transplant
- Melphalan (Alkeran) 220 mg/m2 IV once on day -2
- Dexamethasone (Decadron) 40 mg (route not specified) over 4 days (days not specified)
Stem cells re-infused on day 0
No further treatment.
References
- Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006 Jan 1;107(1):397-403. Epub 2005 Sep 13. link to original article contains verified protocol PubMed
- Update: Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5. link to original article contains verified protocol PubMed
- Update: Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL; IFM Group. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008 Nov 1;112(9):3914-5. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article link to PMC article PubMed
Melphalan, then auto HSCT, then Melphalan & TBI, then auto HSCT
back to top |
Regimen
Study | Evidence |
---|---|
Barlogie et al. 1999 (Total Therapy) | Non-randomized |
This regimen was intended for patients not achieving at least PR after the first transplant.
Chemotherapy, first transplant
- Melphalan (Alkeran) 100 mg/m2 IV once per day on days -3 & -2
Stem cells re-infused on day 0
Chemoradiotherapy, second transplant
- Melphalan (Alkeran) 140 mg/m2 IV once on day -4
- TBI dose of 850 to 1020 cGy in 5 to 6 fractions delivered on days -3 to -1
Stem cells re-infused on day 0
References
- Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999 Jan 1;93(1):55-65. link to original article contains verified protocol PubMed
- Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2495-502. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
Melphalan, then auto HSCT, then RIC allo HSCT
back to top |
Regimen
Study | Evidence |
---|---|
Garban et al. 2006 (IFM99-03) | Non-randomized |
This regimen was meant for patients who had an HLA-identical sibling donor, and is here for historical interest.
Preceding treatment
- VAD induction x 4
Chemotherapy, first transplant
- Melphalan (Alkeran) 200 mg/m2 IV once on day -2
Stem cells re-infused on day 0
After an interval of 2 months, patients proceeded to allogeneic transplant with busulfan, fludarabine, ATG conditioning.
References
- Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5. link to original article contains verified protocol PubMed
- Update: Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL; IFM Group. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008 Nov 1;112(9):3914-5. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007 Mar 15;356(11):1110-20. link to original article PubMed
Melphalan & Methylprednisolone, then auto HSCT
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Child et al. 2003 (MRC Myeloma VII) | Phase III | VBMC | Seems to have superior OS |
Preceding treatment
Chemotherapy
Followed by interferon alfa maintenance.
References
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. link to original article PubMed
Melphalan & TBI, then auto HSCT
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Attal et al. 1996 (IFM90) | Phase III | VMCP/BVAP x 18 | Seems to have superior OS |
Moreau et al. 2002 (IFM 9502) | Phase III | High-dose melphalan & autologous transplant | Might have inferior OS |
Attal et al. 2003 (IFM94) | Phase III | Melphalan, then auto HSCT, then Melphalan & TBI, then auto HSCT | Inferior OS |
Barlogie et al. 2006 (SWOG S9321) | Phase III | VBMCP | To be completed |
Preceding treatment
- IFM90: VMCP alternating with BVAP for 4 to 6 cycles
- IFM 9502 and SWOG S9321: VAD x 3
- IFM 94: VAD x 3 to 4
Chemoradiotherapy
- Melphalan (Alkeran) 140 mg/m2 IV (day not specified)
- Total-body irradiation in 2 Gy fractions once per day x 4 = total dose of 8 Gy, without lung shielding
One course; relative date of stem cell re-infusion not specified
Followed by interferon alfa maintenance.
References
- Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7. link to original article contains verified protocol PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002 Feb 1;99(3):731-5. link to original article PubMed
- Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2495-502. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628. link to original article PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005 Dec 1;106(12):3755-9. Epub 2005 Aug 16. link to original article PubMed
- Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added]. link to original article refers to protocol in Barlogie et al. 1984 PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
Maintenance after first-line therapy
Interferon alfa monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Ludwig et al. 2010 | Phase III | Interferon alfa & Thalidomide | Inferior PFS |
This is of historical interest but is no longer commonly used.
Immunotherapy
References
- Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7. link to original article contains verified protocol PubMed
- Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
- Meta-analysis: Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000 Nov;11(11):1427-36. link to original article PubMed
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83. link to original article PubMed
- Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. link to original article PubMed
- Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010 Sep;95(9):1548-54. Epub 2010 Apr 23. link to original article PubMed
- Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017 Sep;31(9):1922-1927. Epub 2017 Jan 23. link to original article contains verified protocol PubMed
Interferon alfa & Dexamethasone
back to top |
Regimen
Study | Evidence |
---|---|
Bladé et al. 2005 | Non-randomized portion of RCT |
This is of historical interest but is no longer commonly used.
Chemoimmunotherapy
References
- Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005 Dec 1;106(12):3755-9. Epub 2005 Aug 16. link to original article PubMed
Interferon alfa & Thalidomide
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Ludwig et al. 2010 | Phase III | Interferon alfa | Superior PFS |
This is of historical interest but is no longer commonly used.
Chemoimmunotherapy
References
- Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010 Sep;95(9):1548-54. Epub 2010 Apr 23. link to original article PubMed
Relapsed or refractory
EDAP
back to top |
EDAP: Etoposide, Dexamethasone, Ara-C (Cytarabine), Platinol (Cisplatin)
Regimen
Study | Evidence |
---|---|
Barlogie et al. 1989 | Non-randomized |
Chemotherapy
References
- Barlogie B, Velasquez WS, Alexanian R, Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol. 1989 Oct;7(10):1514-7. link to original article PubMed
Pembrolizumab, Pomalidomide, Dexamethasone
back to top |
Regimen
Study | Evidence | ORR |
---|---|---|
Badros et al. 2017 | Phase II | 60% |
This is of historical interest only. While the phase II had a high degree of efficacy (thus meeting our inclusion criteria), subsequent phase III trials were halted by the FDA for excess deaths in this arm; see "Note added in proof" in the paper for more details.
Chemoimmunotherapy
References
- Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1189-1197. Epub 2017 May 1. link to original article PubMed